Advertisement
Advertisement
U.S. markets open in 7 hours 17 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cidara Therapeutics, Inc. (CDTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.4613+0.0169 (+3.80%)
At close: 04:00PM EDT
0.4799 +0.02 (+4.03%)
After hours: 07:57PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close0.4444
Open0.4440
Bid0.0000 x 1800
Ask0.0000 x 900
Day's Range0.4400 - 0.4820
52 Week Range0.4120 - 2.3900
Volume260,482
Avg. Volume274,388
Market Cap31.853M
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CDTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cidara Therapeutics, Inc.
    Technical Assessment: Bearish in the Intermediate-TermFollowing April's miserable performance, May isn't shaping up much better, at least so far. The S&P 500 took a 9% drubbing into April, and 14 trading days into the new month the index is off another (almost) 6%. Since its closing peak on January 3 at 4,796.56, the "500" made a minor new low on Thursday and is down 896 points (or 18.7)%. The Nasdaq has declined 29% from its November 2021 closing high, while the Nasdaq 100 is off 28%.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
Advertisement
Advertisement